July 11, 2026 04:34 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Foreign franchise league enters India! BBL opener to be played in Chennai, announce Modi-Albanese | 'They could have stopped me': Vijay blames police, former DMK government over Karur stampede | 'People will correct their 2025 mistake': Electoral debutant Prashant Kishor predicts BJP defeat in Bankipur | New assassination plot against Trump? Israel's secret intelligence raises alarm amid escalating Middle East tension | Ayatollah Ali Khamenei buried at Iran's holiest shrine as Middle East crisis deepens | Indian techie allegedly kills wife in US, sends photo of her body to 'secret girlfriend' in India; arrested | 'I fled the city': Thane doctor quits after alleged assault by Shiv Sena leader | Sensex surges 500 points before losing steam, ends marginally higher after volatile trading session | US court drops charges against Indian-origin doctor who drove Tesla off 250-foot cliff with family | Dalal Street bleeds! Sensex tanks over 1,600 points after Trump declares Iran ceasefire 'over'
Image credit: UNI

CCI green lights Nirma Ltd's acquisition of Glenmark Life Sciences

| @indiablooms | Dec 20, 2023, at 05:07 am

New Delhi: The Competition Commission of India (CCI) on Tuesday gave its nod to Nirma Limited to acquire the majority shares of Glenmark Life Sciences Limited.

Nirma Limited plans to acquire these shares by purchasing them from Glenmark Life Sciences' promoter and from public shareholders through an open offer, the antitrust watchdog said in a statement.

Nirma Limited has a diverse presence and operations in India and the USA, involved in various products such as soda ash, soaps, detergents, salt, caustic soda, Linear Alkyl Benzene, and other industrial items.

On the other hand, Glenmark Life Sciences is primarily involved in the development, manufacturing, and sale of Active Pharmaceutical Ingredients (APIs) and intermediaries.

It also provides contract development and manufacturing organization (CDMO) services for APIs.

The company's portfolio includes over 130 APIs catering to chronic therapeutic segments like cardiovascular disease, central nervous system disorders, pain management, and anti-diabetics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm